Browse drugs

…ipilimumab/chemotherapy), against KEYNOTE-189, and KEYNOTE-407 (pembrolizumab/chemotherapy). We analyzed both the progression free survival (…

…or the treatment of OX40+ sarcoma and other solid tumors, where HX111 could potentially be a candidate treatment, warranting further …

…n = 4, other/unknown primary n = 17) from patients treated with ipilimumab 3mg/kg and nivolumab 1mg/kg at Thomas Jefferson University were…

…s, followed by curative-intent surgery and one year of adjuvant nivolumab. Primary study endpoints included multiomic profiling of surgic…

…combination with the immune checkpoint inhibitors nivolumab and ipilimumab. We analyzed PBMCs from a subset of patients who demonstrated a…

…II disease (93%). 55% (42/76) were treated with Ipilimumab plus Nivolumab (I/N), 41% (31/76) anti-PD1 monotherapy (PD1) and 4% (3/76) Niv…

…–800.Rohaan MW, et al. Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N. Engl. J. Med. 2022;387:2113–2125.Zacha…

… mutational burden in predicting benefit. In KEAP1-mutant PDXs, WZB117 restored sensitivity to anti-PD-1 therapy, validating translati…

…ng of brain metastases in relation to outcome during first-line ipilimumab plus nivolumab therapy for metastatic melanoma in a community o…

…5784.References Wolchok JD, et al. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. New England Journal of Me…

…, Gravis G, et al. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patient…

…herapy, and 56.7% were stage IV at diagnosis. Patients received nivolumab (10%), pembrolizumab (70%), or ipilimumab/nivolumab combination…